Design of the First Major Heart Safety Trial for the GLP-1 Peptide Drug Lixisenatide in Diabetic Patients
ELIXA enrolled 6,068 diabetic patients with recent heart attacks to test whether the GLP-1 receptor agonist lixisenatide is safe and potentially beneficial for cardiovascular outcomes.
Quick Facts
What This Study Found
The ELIXA trial enrolled 6,068 patients with type 2 diabetes and recent acute coronary syndrome across 49 countries to evaluate whether the GLP-1 receptor agonist peptide lixisenatide affects cardiovascular outcomes. This paper reports the study design and baseline characteristics: participants had a mean age of 60.3 years, mean BMI of 30.2, and average diabetes duration of 9.3 years. The qualifying event was myocardial infarction in 83% and unstable angina in 17%.
ELIXA was the first major cardiovascular outcomes trial of a GLP-1 receptor agonist, designed to evaluate both safety and potential cardiovascular benefit in a high-risk diabetic population.
Key Numbers
How They Did This
Randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. 6,068 patients with T2DM and recent ACS were randomized to lixisenatide or placebo across 49 countries. Enrollment ran from July 2010 to August 2013. The primary endpoint was a composite of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina. Safety data on hypoglycemia, pancreatitis, and malignancy were systematically collected.
Why This Research Matters
This trial was pivotal for the GLP-1 receptor agonist drug class. Following FDA requirements for cardiovascular safety testing of diabetes drugs (post-rosiglitazone), ELIXA set the stage for understanding whether GLP-1 peptide therapies — now among the most prescribed medications worldwide — are safe or beneficial for the heart. The results of this and subsequent GLP-1 RA cardiovascular trials fundamentally shaped treatment guidelines for type 2 diabetes.
The Bigger Picture
ELIXA was a landmark trial in the GLP-1 receptor agonist story. While subsequent trials (LEADER with liraglutide, SUSTAIN-6 with semaglutide) ultimately showed cardiovascular benefits for some GLP-1 RAs, ELIXA was the first to provide rigorous safety data for the class. This trial helped build confidence that peptide-based diabetes drugs were at minimum cardiovascularly safe, paving the way for the current revolution in GLP-1-based therapies.
What This Study Doesn't Tell Us
This is a design and baseline characteristics paper — it does not report outcomes. The study population is specifically high-risk (recent ACS), so findings may not generalize to lower-risk diabetic patients. As a trial of a single GLP-1 RA (lixisenatide), results cannot be assumed to apply to other agents in the class like semaglutide or liraglutide.
Questions This Raises
- ?How did lixisenatide's cardiovascular outcomes compare to the subsequent trials of liraglutide and semaglutide?
- ?Do the cardiovascular effects of GLP-1 receptor agonists differ based on whether patients have acute vs. chronic cardiovascular disease?
- ?What explains the potential differences in cardiovascular benefit between short-acting (lixisenatide) and long-acting (semaglutide) GLP-1 RAs?
Trust & Context
- Key Stat:
- 6,068 patients across 49 countries The first cardiovascular outcomes trial for any GLP-1 receptor agonist, setting the stage for understanding heart safety of the most prescribed peptide drug class
- Evidence Grade:
- This is a strong-grade study in terms of design — a large, multinational, double-blind, placebo-controlled randomized trial. However, this specific paper reports only the design and baseline characteristics, not outcomes.
- Study Age:
- Published in 2015, this design paper preceded the ELIXA results publication. The trial results have since been reported and are now part of the established evidence base for GLP-1 RA cardiovascular safety.
- Original Title:
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
- Published In:
- American heart journal, 169(5), 631-638.e7 (2015)
- Authors:
- Bentley-Lewis, Rhonda, Aguilar, David, Riddle, Matthew C, Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C, Johnston, Peter, Køber, Lars V, Lawson, Francesca, Lewis, Eldrin F, Maggioni, Aldo P, McMurray, John J V, Ping, Lin, Probstfield, Jeffrey L, Solomon, Scott D, Tardif, Jean-Claude, Wu, Yujun, Pfeffer, Marc A
- Database ID:
- RPEP-02585
Evidence Hierarchy
Frequently Asked Questions
What is lixisenatide and how does it relate to drugs like Ozempic?
Lixisenatide is a GLP-1 receptor agonist — a peptide drug that mimics the gut hormone GLP-1 to control blood sugar. It belongs to the same drug class as semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda). Lixisenatide is a shorter-acting version given once daily, while newer agents like semaglutide are given weekly.
Why was this cardiovascular trial required?
After the diabetes drug rosiglitazone was found to increase heart attack risk, the FDA required all new diabetes drugs to undergo rigorous cardiovascular outcomes trials. ELIXA was the first such trial for any GLP-1 receptor agonist, testing whether lixisenatide was safe for the heart in high-risk diabetic patients.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02585APA
Bentley-Lewis, Rhonda; Aguilar, David; Riddle, Matthew C; Claggett, Brian; Diaz, Rafael; Dickstein, Kenneth; Gerstein, Hertzel C; Johnston, Peter; Køber, Lars V; Lawson, Francesca; Lewis, Eldrin F; Maggioni, Aldo P; McMurray, John J V; Ping, Lin; Probstfield, Jeffrey L; Solomon, Scott D; Tardif, Jean-Claude; Wu, Yujun; Pfeffer, Marc A. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.. American heart journal, 169(5), 631-638.e7. https://doi.org/10.1016/j.ahj.2015.02.002
MLA
Bentley-Lewis, Rhonda, et al. "Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.." American heart journal, 2015. https://doi.org/10.1016/j.ahj.2015.02.002
RethinkPeptides
RethinkPeptides Research Database. "Rationale, design, and baseline characteristics in Evaluatio..." RPEP-02585. Retrieved from https://rethinkpeptides.com/research/bentley-lewis-2015-rationale-design-and-baseline
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.